Ables, Iannone, Moore & Associates, Inc. Amgen Inc Transaction History
Ables, Iannone, Moore & Associates, Inc.
- $155 Billion
- Q3 2024
A detailed history of Ables, Iannone, Moore & Associates, Inc. transactions in Amgen Inc stock. As of the latest transaction made, Ables, Iannone, Moore & Associates, Inc. holds 3,364 shares of AMGN stock, worth $1.07 Million. This represents 0.7% of its overall portfolio holdings.
Number of Shares
3,364
Previous 3,364
-0.0%
Holding current value
$1.07 Million
Previous $1.05 Billion
3.12%
% of portfolio
0.7%
Previous 0.7%
Shares
2 transactions
Others Institutions Holding AMGN
# of Institutions
3,084Shares Held
417MCall Options Held
7.18MPut Options Held
6.28M-
Vanguard Group Inc Valley Forge, PA51.9MShares$16.6 Billion0.32% of portfolio
-
Black Rock Inc. New York, NY46MShares$14.7 Billion0.33% of portfolio
-
State Street Corp Boston, MA29MShares$9.25 Billion0.4% of portfolio
-
Primecap Management CO Pasadena, CA14.4MShares$4.61 Billion3.32% of portfolio
-
Morgan Stanley New York, NY14.4MShares$4.58 Billion0.35% of portfolio
About AMGEN INC
- Ticker AMGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 534,931,008
- Market Cap $171B
- Description
- Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...